Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.

@article{Mu2005GefitinibsensitiveMO,
  title={Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.},
  author={Xin Lin Mu and Long Yun Li and Xiao Tong Zhang and Men Zhao Wang and Rui E. Feng and Quan Cai Cui and Hai Sheng Zhou and Bing Qing Guo},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2005},
  volume={11 12},
  pages={4289-94}
}
PURPOSE Studies have shown that mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain are associated with response of lung cancer to gefitinib (Iressa, AstraZeneca Corp., Shanghai, China). A higher incidence of EGFR mutation was observed in non-small cell lung cancer (NSCLC) patients of Japanese origin compared with those of American origin. However, no data about such mutations in Chinese patients with NSCLC could be obtained. METHODS Primary NSCLC tissues were… CONTINUE READING